EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Betagenin and the Gut–Pancreas Axis: A Candidate Intestine-Derived Signal for β-Cell Function and Survival in Diabetes Mellitus

Tomotaka Yokoo, Hideo Toyoshima

Metabolites · 2026-11-11 · 16 (11) · 877

DOI: 10.3390/metabo16110877 ↗
AbstractBibliografische Angaben

Abstract

Pancreatic β-cell dysfunction and progressive loss of functional β-cell mass are central features of both type 1 and type 2 diabetes mellitus, although the mechanisms driving β-cell failure differ between these disorders. Current glucose-lowering therapies improve glycemic control and reduce cardiometabolic risk but do not consistently restore endogenous β-cell mass in established diabetes mellitus. The gut–pancreas axis has traditionally been defined by the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). However, the intestine produces additional signals that may influence β-cell function, survival, and regenerative capacity. Betagenin is a recently identified intestine-derived peptide generated from the Tm4sf20 gene product. An approximately 10-kDa betagenin-immunoreactive peptide was detected in the circulation of wild-type mice. The initial study reported that betagenin enhanced glucose-stimulated insulin secretion (GSIS), increased cell-cycle-associated responses in β-cell models and islet preparations, and reduced β-cell apoptosis. Pharmacological evidence implicated MEK–ERK1/2 signaling in selected responses. In isolated human islets, betagenin enhanced GSIS and increased 5-ethynyl-2′-deoxyuridine (EdU) incorporation, although the identity and fate of EdU-positive cells remain unresolved. In streptozotocin-induced diabetic mice, administration of synthetic betagenin and adenovirus-mediated betagenin expression improved hyperglycemia and were associated with recovery of estimated β-cell mass. These findings are preclinical; responses in isolated human islets do not establish clinical efficacy in patients or durable regeneration of functional human β-cells. This review examines betagenin as a candidate circulating component of the gut–pancreas axis and discusses its potential to influence β-cell function, survival, and recovery after injury. We also address key questions concerning physiological regulation of endogenous betagenin, receptor identification, β-cell specificity in human islets, pharmacokinetics, long-term safety, and therapeutic relevance in progressive type 2 diabetes mellitus.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →